SCHEMBL2949666

SCHEMBL2949666

COCCOc1ccc(C(CC(=O)O)c2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.62
SMN1; SMN2 Q16637 2/20 0.57
HPGD P15428 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
POLB P06746 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GPR88 Q9GZN0 2/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 2/20 0.48
NPSR1 Q6W5P4 1/20 0.47
PKM P14618 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946000 0.93 FFAR1 (0.60) FFAR1SMN1; SMN2HPGDTDP1POLB
SCHEMBL2947981 0.86 SMN1; SMN2 (0.74) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL2948148 0.86 FFAR1 (0.68) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL13236808 0.85 SMN1; SMN2 (0.49) FFAR1SMN1; SMN2HPGDTDP1GPR88
SCHEMBL2947112 0.84 FFAR1 (0.60) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL2941508 0.84 MMP9 (0.65) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL2939675 0.84 FFAR1 (0.64) FFAR1SMN1; SMN2HPGDTDP1POLB
SCHEMBL13264702 0.83 FFAR1 (0.71) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL2949131 0.82 MMP9 (0.67) FFAR1SMN1; SMN2TDP1POLBL3MBTL1
SCHEMBL2939695 0.82 MMP9 (0.67) FFAR1SMN1; SMN2TDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US claimed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US claimed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176912-A1 GPR40 AGONISTS GPR119, GPR65, GPR55 FFAR1 8/4885SMN1; SMN2 3652/4885HPGD 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.